Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.
Adult
Antibodies, Neutralizing
/ biosynthesis
Antibodies, Viral
/ biosynthesis
Betacoronavirus
/ immunology
COVID-19
Case-Control Studies
Convalescence
Coronavirus Infections
/ blood
Female
Humans
Male
Middle Aged
Neutralization Tests
Pandemics
Pneumonia, Viral
/ blood
SARS-CoV-2
Severity of Illness Index
Journal
Signal transduction and targeted therapy
ISSN: 2059-3635
Titre abrégé: Signal Transduct Target Ther
Pays: England
ID NLM: 101676423
Informations de publication
Date de publication:
02 09 2020
02 09 2020
Historique:
received:
23
06
2020
accepted:
14
08
2020
revised:
29
07
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
17
9
2020
Statut:
epublish
Résumé
COVID-19 patients exhibit differential disease severity after SARS-CoV-2 infection. It is currently unknown as to the correlation between the magnitude of neutralizing antibody (NAb) responses and the disease severity in COVID-19 patients. In a cohort of 59 recovered patients with disease severity including severe, moderate, mild, and asymptomatic, we observed the positive correlation between serum neutralizing capacity and disease severity, in particular, the highest NAb capacity in sera from the patients with severe disease, while a lack of ability of asymptomatic patients to mount competent NAbs. Furthermore, the compositions of NAb subtypes were also different between recovered patients with severe symptoms and with mild-to-moderate symptoms. These results reveal the tremendous heterogeneity of SARS-CoV-2-specific NAb responses and their correlations to disease severity, highlighting the needs of future vaccination in COVID-19 patients recovered from asymptomatic or mild illness.
Identifiants
pubmed: 32879307
doi: 10.1038/s41392-020-00301-9
pii: 10.1038/s41392-020-00301-9
pmc: PMC7464057
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
180Références
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Nature. 2016 Mar 3;531(7592):118-21
pubmed: 26935699
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Immunity. 2020 Aug 18;53(2):442-455.e4
pubmed: 32668194
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Am J Pathol. 2020 Aug;190(8):1680-1690
pubmed: 32473109
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
Cell Mol Immunol. 2020 Jun;17(6):647-649
pubmed: 32313207
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cell Rep. 2020 Jul 21;32(3):107918
pubmed: 32668215
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330